Consistent with these experimental and clinical findings, our intervention study shows that intravenous supplementation of human albumin at a dose of 10 g every 2 weeks for 24 weeks yields benefit on daily function and dementia severity in AD patients. This evidence concerns the gene ALB and Alzheimer disease.